Top news of the week: 22.07.2022.
Women of Color in Biopharma: Overcoming Barriers and Fighting for a Seat at the Table
Women of color continue to be trailblazers in the life science industry, proving that they can be just as, if not more, successful than their peers - even if it isn’t always easy.
Roche Inks Potential $1B AAV Vector Deal with Avista for Eye Disease
Avista Therapeutics inked a partnership deal with Swiss pharma giant Roche to develop AAV gene therapy vectors for eye diseases.
High-Tech Smell Sensors Aim to Sniff Out Disease, Explosives—and Even Moods
Advances in artificial intelligence, bioengineering and synthetic biology are powering a new breed of odor sensors, some using living cells.
Battle of the Patents: Daiichi Sankyo, Seagen, Alnylam, CureVac, Pfizer, BioNTech & Moderna
The LPN technology used in the mRNA COVID-19 vaccines has been the target of numerous patent challenges. Here's a look at recent biopharma patent disputes.
Ultragenyx Buys GeneTx to Take Angelman ASO the Distance
The buyout comes on the heels of promising Phase I/II results from GTX-102, an antisense oligonucleotide candidate being developed to treat Angelman syndrome.
Exclusive: Mark Pruzanski is once again reaching for the brass ring in biotech
Mark Pruzanski spent more than 18 years growing Intercept from a startup to a commercial player looking for a landmark approval treating NASH. But 19 months after he stepped aside from his ...
After 14 years as Roche’s CEO, Severin Schwan is passing the baton
Roche CEO Severin Schwan will be moving to the board chairman role in a few months, making room for Thomas Schinecker — the current chief of the diagnostics division — to take the helm of ...
Scoop: AbbVie terminates early-stage study of I-Mab's antibody, another clinical setback in CD47 field
The CD47 field faced setbacks earlier this year when Gilead’s magrolimab was hit with partial clinical holds, and another clinical hurdle can be added to the list, with AbbVie terminating a ...